Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Race Oncology Ltd. ( (AU:RAC) ) has shared an announcement.
Race Oncology Ltd has announced an investor webinar to discuss the discovery of the primary anticancer mechanism of action for its lead asset, (E,E)-bisantrene (RCDS1). The webinar, featuring key company executives, will provide insights into the discovery’s potential impact on future clinical and commercial plans, offering stakeholders an opportunity to engage directly with the company’s leadership.
More about Race Oncology Ltd.
Race Oncology (ASX: RAC) is a clinical stage biopharmaceutical company focused on cancer care. Its lead asset, RCDS1 (E,E-bisantrene), is an anticancer agent targeting cancer growth regulator MYC, with applications in various oncology indications. The company is advancing RC220, a formulation of RCDS1, for use in combination with anthracyclines, and exploring partnerships to enhance global access.
Average Trading Volume: 342,514
Technical Sentiment Signal: Buy
Current Market Cap: A$690.1M
For a thorough assessment of RAC stock, go to TipRanks’ Stock Analysis page.